The metabolic syndrome in women: A growing problem for cardiac risk

Journal of Cardiovascular Nursing

Volumn 20, Issue 6, 2005, Pages 427-432

  Paul, Sara ^a   Smith, Lanna ^a  

^a Western Piedmont Heart Center   (United States)

Author keywords

Cardiovascular disease; Dyslipidemia; Hypertension; Insulin resistance; Menopause; Metabolic syndrome; Obesity; Polycystic ovarian syndrome

Indexed keywords

CARDIOVASCULAR DISEASE; FEMALE; HUMAN; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; METABOLIC SYNDROME X; OBESITY; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS;

EID: 33644856103     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200511000-00011     Document Type: Article

References (63)

1. American Heart Association. Heart disease and stroke statistics-2005 update. Available at:. Accessed February 9, 2005.
2. Carr M. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404-2411.
3. National Heart, Lung and Blood Institute. 3rd Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. Baltimore: National Institutes of Health; May 2001. 01-3670.
4. Grundy S, Brewer HB, Cleeman J, Smith SC, Lenfant C for the conference participants. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
5. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
6. Park Y, Zhu S, Palaniappan L, Heshka S, Carnethon M, Heymsfield S. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-436.
7. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation. 2003; 108:414-419.
8. Flegal K, Carroll M, Ogden C, Johnson C. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
9. Wilson P, Kannel W, Silbershatz H, D'Agostino R. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-1109.
10. Grundy S, Hansen B, Smith S, Cleeman J, Kahn R for the conference participants. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-556.
11. Knopp R. Risk factors for coronary artery disease in women. Am J Cardiol. 2002;89:28E-34E.
12. Hulley S, Rosenman R, Bawol R, Brand R. Epidemiology as a guide to clinical decisions. The association between triglycerides and coronary heart disease. N Engl J Med. 1980;302:1383-1389.
13. Gohlke-Barwolf C. Coronary artery disease: is menopause a risk factor? Basic Res Cardiol. 2000;95(suppl 1):177-183.
14. Kannel W, Wilson P. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 1995;155:57-61.
15. Tremollieres F, Pouilles J, Cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis. 1999;142:415-423.
16. Harrison-Bernard L, Raij L. Postmenopausal hypertension. Curr Hypertens Rep. 2000;2:202-207.
17. Fisman E, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep. 2002;4:464-470.
18. Owens J, Stoney C, Matthews K. Menopausal status influences ambulatory blood pressure levels and blood pressure changes during mental stress. Circulation. 1993; 88:2794-2802.
19. Reckelhoff J. Gender differences in the regulation of blood pressure. 2001;37:1199-1208.
20. Mendelsohn M. Protective effects of estrogen on the cardiovascular system. Am J Cardiol. 2002;89(suppl 12):12E-17E.
21. Rosenthal T, Oparil S. Hypertension in women. J Hum Hypertens. 2000;14:691-704.
22. Deedwania P. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation. 2004;109:2-4.
23. Carey D, Jenkins A, Campbell L, Freund J, Chisholm D. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45:633-638.
24. Daly P, Solomon C, Manson J. Risk modification in the obese patient. In: Manson J, Ridker P, Gaziano J, et al, eds. Prevention of Myocardial Infarction. New York: Oxford University Press; 1996:203-240.
25. Stevens J, Couper D, Pankow J, et al. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res. 2001;9:696-705.
26. Wei M, Gaskill S, Haffner S, Stern M. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans: a 7-year prospective study. Obes Res. 1997;5:16-23.
27. Han T, Williams K, Sattar N, Hunt K, Lean M, Haffner S. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res. 2002;10:923-931.
28. Bjorntorp P. The associations between obesity, adipose tissue distribution adn disease. Acta Med Scand Suppl. 1988;723:121-134.
29. Vague J, Vague P, Tramoni M, Vialettes B, Mercier P. Obesity and diabetes. Acta Diabetol Lat. 1980;17:87-99.
30. Wilson P, Kannel W. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol. 2002;11:119-123.
31. Kenchaiah S, Evans J, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313.
32. Guo S, Zeller C, Chumlea W, Siervogel R. Aging, body composition, and lifestyle: the Fels Longitudinal Study. Am J Clin Nutr. 1999;70:405-411.
33. Kuller L, Meilahn E, Lassila H, Matthews K, Wing R. Cardiovascular risk factors during first five years postmenopause in nonhormone replacement users. In: Forte T, ed. Hormonal, Metabolic and Cellular Influences on Cardiovascular Disease in Women.Armonk: Futura; 1997:273-287.
34. Garaulet M, Perez-Llamas F, Baraza J, et al. Body fat distribution in pre- and post-menopausal women: metabolic and anthropometric variables. J Nutr Health Aging. 2002; 6:123-126.
35. Steinbaum S. The metabolic syndrome: an emerging health epidemic in women. Prog Cardiovasc Dis. 2004; 46:321-336.
36. Kip K, Marroquin O, Kelley D, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) Study. Circulation. 2004; 109:706-713.
37. Saltiel A, Kahn C. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806.
38. Ferrannini E, Haffner S, Mitchell B, Stern M. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-422.
39. Reaven G. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
40. Abbasi F, Brown B, Lamendola C, McLaughlin T, Reaven G. Relationship between obesity, insulin resistance and coronary heart disease risk. J Am Coll Cardiol. 2002;40: 937-943.
41. Walden C, Knopp R, Wahl P, Beach K, Strandness E. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med. 1984;311:953-959.
42. Siegel R, Cuples A, Schaefer E, Wilson P. Lipoproteins, apolipoproteins and low-density lipoprotein size among diabetics in the Framingham Offspring Study. Metabolism. 1996;45:1267-1272.
43. Zindrou D, Taylor K, Bagger J. Admission plasma glucose: an independent risk factor in nondiabetic women after coronary artery bypass grafting. Diabetes Care. 2001;24:1634-1639.
44. Lindheim S, Buchanan T, Duffy D, et al. Comparison of estimates of insulin sensitivity in pre and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Invest. 1994;1:150-154.
45. Guthrie J, Ball M, Dudley E, et al. Impaired fasting glycaemia in middle-aged women: a prospective study. Int J Obes Relat Metab Disord. 2001;25:646-651.
46. Rosano G, Vitale C, Silvestri A, Fini M. The metabolic syndrome in women: implications for therapy. Int J Clin Pract. 2004;139(suppl):20-25.
47. Sjoberg L, Daaja R, Tuomilehto J. Epidemiology of postmenopausal hypertension. Int J Clin Pract. 2004;139:4-12.
48. Austin M, Breslow J, Hennekens C, Buring J, Willett W, Krauss R. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260: 1917-1921.
49. Berra K. Treatment options for patients with the metabolic syndrome. J Am Acad Nurse Pract. 2003;15:361-369.
50. Rassouw J, Anderson G, Prentice R, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
51. Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684.
52. Grodstein F, Clarkson T, Manson J. Understanding the divergent data on post-menopausal hormone therapy. N Engl J Med. 2003;348:645-650.
53. Solomon C, Diuhy R. Rethinking post-menopausal hormone therapy. N Engl J Med. 2003;348:579-580.
54. Sharpless J. Polycystic ovary syndrome and the metabolic syndrome. Clin Diabetes. 2003;21:154-161.
55. Richardson M. Current perspectives in polycystic ovary syndrome. Am Fam Phys. 2003;68:697-704.
56. Hunter M, Sterrett J. Polycystic ovary syndrome: it's not just infertility. Am Fam Phys. 2000;62:1079-1188.
57. Cobin R, Futterweit W, Nestler J, et al. American Association of Clinical endocrinologists position Statement of Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Available at:. Accessed February 11, 2005.
58. Hopkinson Z, Sattar S, Fleming R, Greer I. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. Br Med J. 1998;317:329-332.
59. Schroeder B, American College of Obstetricians and Gynecologists. ACOG releases guidelines on diagnosis and management of polycystic ovary syndrome. Am Fam Phys. 2003;67:1619-1620, 1622.
60. Adams M, Williams J, Kaplan J. Effects of androgens on coronary artery atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol. 1995;15:562-570.
61. Phillips G, Pinkernell B, Jing T. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 1997;17:695-701.
62. Paradisi G, Steinberg H, Hempfling A, et al. Polyststic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001;103:1410-1415.
63. Talbott E, Guzick D, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000;20:2414-2421.